LEO Pharma appoints Marika Murto to lead Global Product Strategy
- Marika Murto brings over 20 years of pharmaceutical expertise in product strategy, innovation, and business transformation
- Her appointment as SVP of Global Product Strategy will help unlock LEO Pharma’s portfolio potential, driving patient impact and supporting sustainable growth
Ballerup, Denmark, December 16, 2025 – LEO Pharma, a global leader in medical dermatology, announces the appointment of Marika Murto, PhD, as SVP of Global Product Strategy and member of the Global Leadership Team.
Marika joins LEO Pharma from Amgen, where she most recently served as Associate Vice President and U.S. Commercial Lead for Bone Health, driving strategic brand positioning and cross‑functional collaboration. Her career at Amgen included senior global and affiliate leadership roles, including General Manager for the Netherlands, Global Product Team Lead for Bone Health, and Country Director for Finland. She has also held senior commercial positions at Pfizer and Roche, gaining expertise across oncology, vaccines, specialty medicines, and portfolio strategy.
“I’m very excited to join LEO Pharma and lead Global Product Strategy at such an important point in the company’s journey. Effective product strategy is about uniting great science, market insight, and organizational excellence to create meaningful results for patients. I’m passionate about empowering diverse, results driven teams and embedding innovation in all that we do,” says Marika Murto.
With her deep global experience and ability to combine scientific understanding with strategic execution, Marika will play a key role in shaping the direction of LEO Pharma’s portfolio, ensuring it is positioned to deliver strong impact for patients and sustainable growth for the company.
“Marika’s strong international background, strategic mindset, and ability to connect vision with delivery make her an outstanding choice to lead Global Product Strategy. She has shown throughout her career that she can shape complex portfolios and succeed across diverse markets. I very much look forward to welcoming her to the LEO Pharma team,” says Christophe Bourdon, CEO.
“I’d like to sincerely thank Lisa Elliot for stepping in as interim head of Global Product Strategy during this important period. I’m truly pleased that she will continue to contribute her expertise, dedication, and deep knowledge of our company in her previous role within Global Asset & Payer Strategy,” says Christophe.
Marika Murto will join LEO Pharma as Senior Vice President of Global Product Strategy on February 1, 2026.
-- ENDS --
Kontakter
Jeppe IlkjærGlobal Communications
Tlf:+45 3050 2014JEILK@leo-pharma.comAbout LEO Pharma
LEO Pharma is a global leader in medical dermatology. We deliver innovative solutions for skin health, building on a century of experience with breakthrough medicines in healthcare. We are committed to making a fundamental difference in people’s lives, and our broad portfolio of treatments serves close to 100 million patients in over 70 countries annually. LEO Pharma is co-owned by majority shareholder the LEO Foundation and, since 2021, Nordic Capital. Headquartered in Denmark, LEO Pharma has a team of 4,000 people worldwide. Together, we reach far beyond the skin.
For more information, visit www.leo-pharma.com.
Følg pressemeddelelser fra LEO Pharma
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra LEO Pharma
LEO Pharma submits adolescent label expansion application for Anzupgo® to EMA15.12.2025 09:00:00 CET | Pressemeddelelse
LEO Pharma has submitted a label expansion application to EMA to expand Anzupgo® (delgocitinib) cream to adolescent patients (12–17 years) with moderate to severe chronic hand eczema (CHE) for whom topical corticosteroids are inadequate or inappropriate – the application has been accepted for review. The application is supported by results from DELTA TEEN, a phase 3 trial investigating efficacy and safety of Anzupgo® in adolescents with moderate to severe chronic hand eczema (CHE).1 The label expansion submission for adolescent patients demonstrates LEO Pharma's commitment to investigating use within relevant sub-populations where treatments can help make a fundamental difference for patients with skin diseases.
LEO Pharma Announces Positive Topline 32-Week Key Results in ADHAND Trial17.11.2025 09:00:00 CET | Pressemeddelelse
The ADHAND trial evaluates the efficacy and safety of tralokinumab in adult patients living with atopic dermatitis with moderate-to-severe hand involvement,1 a high burden, high unmet need population.2 At Week 16, tralokinumab showed statistically significant improvement compared to placebo in all primary and key secondary endpoints such as clear or almost clear skin, itch and pain.3 The 32-week results of the ADHAND trial builds on the positive findings observed at Week 16.
LEO Pharma delivers 8% revenue growth at CER in 9M 2025 and updates full-year outlook6.11.2025 09:00:00 CET | Pressemeddelelse
Ballerup, Denmark, 6 November, 2025 - In the first nine months of 2025, LEO Pharma continued its robust revenue growth, with significantly improved profitability and free cash flow. As expected, growth accelerated in the third quarter, with the global rollout of Anzupgo® gaining further momentum after its September launch in the U.S. The 2025 financial outlook is updated to reflect the addition of Spevigo® to the portfolio, reinforcing LEO Pharma’s commitment to advancing innovation and expanding access to care. Highlights LEO Pharma’s revenue increased by 7% to DKK 10,064 million, and by 8% at constant exchange rates (CER), entirely driven by organic growth. The revenue growth was led by North America (+27% at CER), with Europe (+2% at CER) and Rest of World (+6% at CER) also contributing to the overall growth. Revenue from the Dermatology portfolio grew by 9% (CER), driven by the Strategic brands Adtralza®/Adbry® and Anzupgo®, which combined had a revenue increase of 41% (CER), in ad
LEO Pharma announces NICE recommendation of reimbursement in England and Wales5.11.2025 12:00:00 CET | Pressemeddelelse
The National Institute for Health and Care Excellence (NICE) has recommended the first-and-only topical treatment for adults in the United Kingdom specifically approved for moderate to severe chronic hand eczema (CHE) for whom topical corticosteroids are inadequate or inappropriate.1 The Technology Appraisal Guidance (TAG) means NHS organisations in England and Wales must now make Anzupgo® ▼(delgocitinib) cream available for healthcare professionals to prescribe. CHE affects around 4.4 million2,3 adults in the UK, with 70% of those with severe forms reporting problems performing everyday activities4, and 58% saying it interferes with their ability to work5.
LEO Pharma strengthens leadership in medical dermatology with the appointment of Sophie Lamle as Chief Development Officer3.11.2025 12:00:00 CET | Pressemeddelelse
Sophie Lamle brings over 20 years of experience in the pharmaceutical industry, leading innovation, clinical development, and strategic transformation. Her appointment will further strengthen LEO Pharma’s Search & Develop innovation model, unlocking value with a focus on differentiated assets.
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum